Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
34.9M
-
Shares change
-
+5.78M
-
Total reported value, excl. options
-
$150M
-
Value change
-
+$25.4M
-
Put/Call ratio
-
0.47
-
Number of buys
-
51
-
Number of sells
-
-32
-
Price
-
$4.29
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q3 2021
126 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q3 2021.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.9M shares
of 193M outstanding shares and own 18.04% of the company stock.
Largest 10 shareholders include BlackRock Inc. (5.94M shares), RTW INVESTMENTS, LP (4.73M shares), VANGUARD GROUP INC (3.77M shares), Hudson Bay Capital Management LP (1.8M shares), STATE STREET CORP (1.66M shares), GEODE CAPITAL MANAGEMENT, LLC (1.54M shares), ADVISOR GROUP HOLDINGS, INC. (1.36M shares), Nuveen Asset Management, LLC (1.12M shares), MILLENNIUM MANAGEMENT LLC (1.02M shares), and Point72 Asset Management, L.P. (895K shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.